IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells
Sherlock JP. et al, (2017), Nature Medicine, 18, 1069 - 76
Spondyloarthropathy: interleukin 23 and disease modification
Sherlock J. et al, (2017), The Lancet, 385, 2017 - 2018
The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases.
Sherlock J. et al, (2017), Current Opinion in Rheumatology, 27, 71 - 75
The critical role of interleukin-23 in spondyloarthropathy
Sherlock J. et al, (2017), Molecular immunology, 57, 38 - 43
What can rheumatologists learn from translational cancer therapy?
Sherlock JP. et al, (2017), Arthritis Research & Therapy, 15
The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases
Sherlock JP. et al, (2015), Current Opinion in Rheumatology, 27, 71 - 75
IL-23 in health and disease
Sherlock JP. et al, (2014), Cytokine Frontiers: Regulation of Immune Responses in Health and Disease, 179 - 198
The critical role of interleukin-23 in spondyloarthropathy.
Sherlock JP. et al, (2014), Mol Immunol, 57, 38 - 43
Interleukin-23: a promising therapeutic target in seronegative spondyloarthropathy.
Sherlock JP. and Cua DJ., (2013), Curr Opin Pharmacol, 13, 445 - 448
Interleukin 23 is critical in the pathogenesis of spondyloarthropathy and acts on a novel population of interleukin 23R+entheseal resident cells
Sherlock JP. et al, (2013), LANCET, 381, 14 - 14